Fig. 6
From: NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
A proposed mechanism of action for NG2 antagonists. NG2 is well established to bind to common components of the extracellular matrix including collagen [40, 41, 57]. This supports a model in which in vivo blockade of NG2 may disrupt the interaction between MLLr-B-ALL blasts and BM stroma, promoting the mobilization of MLLr-B-ALL blasts into PB, thus overriding BM stroma-mediated chemoprotection and making leukemic cells more accessible (sensitive) to conventional chemotherapy
